Loading...

PAVmed Inc

PAVMZNASDAQ
Healthcare
Medical - Devices
$0.001
$-0.00(-40.00%)

PAVmed Inc (PAVMZ) Stock Overview

Explore PAVmed Inc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.8/100

Key Financials

Market Cap11.9K
P/E Ratio0.12
EPS (TTM)N/A
ROE0.01%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$0.06
1 Year Target$0.07

PAVMZ Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of PAVmed Inc (PAVMZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.07.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.12 and a market capitalization of 11.9K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for PAVMZStats details for PAVMZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PAVMZAnalyst Recommendations details for PAVMZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO

Dr. Lishan Aklog M.D.

Employees

39

Headquarters

360 Madison Avenue, New York City, DE

Founded

2018

Frequently Asked Questions

;